Oyvind Dahle


Oyvind Dahle works with organizations to provide patent protection of technologies, such as chemical compounds and polymers, pharmaceutical compositions and delivery systems; immunotherapeutics using engineered antigen binding proteins, such as multispecific immunoglobulin-based molecules and chimeric antigen receptor T cell receptors; stem cell therapy; genetic modification technologies, such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR); artificial intelligence-based drug discovery and diagnostics; diagnostic methods, such as liquid biopsy; next-generation sequencing (NGS), multiplex PCR, single-cell sequencing, and medical devices. In addition to drafting and prosecuting patents, Oyvind has experience with providing patentability, invalidity, and freedom-to-operate opinions, and representing patent owners on appeals and inter partes reviews before the Patent Trial and Appeal Board (PTAB). He is a member of the firm’s Chemical, Biotechnology & Pharmaceutical Practice.

Oyvind joined Foley & Lardner as an associate in 2016, and prior to that, he externed at the U.S. Patent and Trademark Office’s Office of Patent Legal Administration, where he gained experience in patent examination procedures and assessments.

Oyvind also has extensive experience as a scientist and has a Ph.D. in biochemistry. In particular, he has worked at Leidos, Inc. as a scientist, at the National Cancer Institute’s Laboratory of Protein Dynamics and Signaling as a research fellow, and at the National Cancer Institute in its Experimental Immunology Branch as a postdoctoral fellow. At the National Cancer Institute, Oyvind conducted research on the development and function of the immune system, the pathology of cancer such as multiple myeloma, stem cell function and applications, and early embryonic development.

Presentations and Publications

  • Author, “The Absurdity of Patent Ineligible Categories: The Discrepancy Between the Ariosa and Cellzdirect Decisions Highlights the Problems Created by Formalistic Adjudication of Patent Eligibility,” Wake Forest Journal of Business and Intellectual Property Law, Vol. 17 No. 1 (2016)
  • Co-author, “Inhibiting Smad2/3 Signaling in Pluripotent Mouse Embryonic Stem Cells Enhances Endoderm Formation by Increasing Transcriptional Priming of Lineage-Specifying Target Genes,” Developmental Dynamics, Vol. 245 Issue 7 (2016)
  • Co-author, “Polycomb Determines Responses to Smad2/3 Signaling in Embryonic Stem Cell Differentiation and in Reprogramming,” Stem Cells, Vol. 31 Issue 8 (2013)
  • Presenter, “Epigenetics in Development Polycomb Determines Smad2/3 Responses During Cell Fate Transitions in Stem Cell Differentiation and Reprogramming,” National Institutes of Health, Maryland (2013)
  • Co-author, “Nodal Signaling Recruits Histone Demethylase Jmjd3 to Counteract Polycomb Repression at Target Genes,” Science Signaling, Vol. 3 Issue 127 (2010)
  • Co-author, “FLASH Acts as a Co-activator of the Transcription Factor c-Myb and Localizes to Active RNA Polymerase II Foci,” Oncogene, Vol. 27 (2008)
  • Co-author, “The Chromatin Remodeling Factor Mi-2 Acts as a Novel Co-activator for Human c-Myb,” The Journal of Biological Chemistry, Vol. 282 (2007)
  • Co-author, “Coreceptor Signal Strength Regulates Positive Selection but Does Not Determine CD4/CD8 Lineage Choice in a Physiologic in Vivo Model,” The Journal of Immunology, Vol. 177 Issue 10 (2006)
  • Co-author, “PML Mediates IFN-alpha-induced Apoptosis in Myeloma by Regulating TRAIL Induction,” Blood, Vol. 105 (2005)
  • Co-author, “c-Myb Associates with PML in Nuclear Bodies in Hematopoietic Cells,” Experimental Cell Research, Vol. 297 Issue 1 (2004)
  • Co-author, “Transactivation Properties of c-Myb Are Critically Dependent on Two SUMO-1 Acceptor Sites That Are Conjugated in a PIASy Enhanced Manner,” European Journal of Biochemistry, Vol. 270 (2003)
  • Co-author, “JAB1/CSN5 Interacts with the GAL4 DNA Binding Domain: A Note of Caution About Two-Hybrid Interactions,” Biochimie, Vol. 83 Issue 10 (2001)


  • Norwegian
11 December 2023 Innovative Technology Insights

AI in Health Care: Powering Patient Outcomes

Welcome to AI in Health Care: Powering Patient Outcomes. In this eBook, our contributors examine this intersection through lenses including its impact on merger activity, antitrust enforcement, patent prosecution, and more.
23 October 2023 Innovative Technology Insights

Safeguarding AI Innovation in Stem Cell Therapy

The use of artificial intelligence to advance stem cell therapy has produced exciting results, with a key role in driving recent growth and innovation.
23 May 2023 Health Care Law Today

Sequencing the Impact: How AI is Boosting Genomic Medicine

The rapid development of AI systems will significantly impact businesses that rely on genomic data analysis for research and development of therapeutics and diagnostic decision-making.
21 July 2022 Blogs

Artificial Intelligence Enters Stem Cell Research

With Artificial Intelligence increasingly embraced for research and development purposes, our team analyzes a recent breakthrough where AI was used to improve the production of stem cells in a laboratory environment.
15 July 2022 In the News

Oyvind Dahle and Michael Pontrelli Author Article on Recent Advancement in Human Genomics

Foley & Lardner LLP Partner Michael Pontrelli and Associate Oyvind Dahle collaborated to author the Drug Discovery World article, “Why a Recent Advancement is a Giant Leap for Human Genomics”, discussing the implications of the first complete, gapless sequence of the human genome.
09 October 2018 Blogs

Federal Circuit Takes A Narrow View Of Reasonable Expectation Of Success

The Federal Circuit decision in<EM> Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc</EM>. addressed several aspects of obviousness doctrine.